Compare Vanguard S&P 500 ETF (VOO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 ETF vs Zoetis Inc — how do they compare? Vanguard S&P 500 ETF trades at $710.42, while Zoetis Inc trades at $73.54 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VOO | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $710.71 | $156.76 |
52-Week Low | $580.93 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOO trades at $710.69 with minimal daily movement (+0.01%), maintaining a bullish technical stance as the S&P 500 ETF approaches record highs. The overall technical signal is bullish with strong moving average support, though oscillators show neutral momentum. Recent news highlights the S&P 500's elevated valuation levels while institutional interest remains strong, with Bay Colony Advisory increasing its position by 8.6% in Q2 2026.
The ETF's outlook remains positive given its core exposure to large-cap US equities, but investors face valuation concerns with the S&P 500 trading at historically high multiples. Key risks include market volatility around inflation data and potential profit-taking near resistance levels, while institutional accumulation suggests continued confidence in the broader market trajectory.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
